NEW YORK (GenomeWeb) – Veracyte has appointed Cepheid Chairman and CEO John Bishop to its board of directors. He also will join the board's compensation committee. Bishop replaces Samuel Colella, who resigned from the board, effective Nov. 30.

Bishop has a long track record in the molecular diagnostics industry, previously serving as president and CEO of Vysis, which was acquired by Abbott Laboratories; chairman and CEO of MicroProbe; and president and COO of Gen-Probe, among other executive positions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.